Idiopathic Pulmonary Fibrosis
📧 Sign up to get email alerts when something new happens for Idiopathic Pulmonary Fibrosis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-12-14FDA Approved: PIRFENIDONE — Supplemental Application (Laurus Labs Limited)
FDA approved a supplemental application for pirfenidone from Laurus Labs Limited. Pirfenidone is used to treat idiopathic pulmonary fibrosis…
-
CLINICAL_TRIALS trial_result · 2023-12-12Clinical Trial Update: Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/ [Phase 2]
Phase 2a trial evaluating PLN-74809 on αvβ6 receptor occupancy in idiopathic pulmonary fibrosis; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-12-11Clinical Trial Update: JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF [Phase 2]
Phase 2 trial update for ND-L02-s0201 in idiopathic pulmonary fibrosis has been completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: Families-At-risk for Interstitial Lung Disease Study
Completed clinical study investigating families at risk for interstitial lung disease and idiopathic pulmonary fibrosis; results posted.
-
CLINICAL_TRIALS trial_result · 2023-11-02Clinical Trial Update: A Clinical Trial on the Treatment of Idiopathic Pulmonary Fibrosis [Phase 2]
Phase 2 clinical trial update for a treatment of idiopathic pulmonary fibrosis.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-10-23Clinical Trial Update: Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis [Phase 1]
Phase 1 trial assessing safety, tolerability, and pharmacokinetics of TRK-250 in idiopathic pulmonary fibrosis completed; results posted.
-
FDA approval · 2023-09-12FDA Approved: PIRFENIDONE — Supplemental Application (Micro Labs Limited)
The FDA approved a supplemental application for a generic pirfenidone from Micro Labs Limited, authorizing the generic product's approval. T…
-
CLINICAL_TRIALS trial_result · 2023-08-31Clinical Trial Update: Clinical Efficacy and Safety of Autologous Lung Stem Cell Transplantation in Patients With Idiopathic Pulmonary Fibrosis [Phase 1, Phase 2]
Phase 1/2 trial investigating autologous lung stem cell transplantation for safety and efficacy in idiopathic pulmonary fibrosis has complet…
-
CLINICAL_TRIALS trial_result · 2023-08-31Clinical Trial Update: Nandrolone Decanoate in the Treatment of Telomeropathies [Phase 1, Phase 2]
Phase 1/2 clinical trial of nandrolone decanoate for telomeropathies, including aplastic anemia and bone marrow failure syndromes, has compl…
-
FDA approval · 2023-08-07FDA Approved: PIRFENIDONE — Supplemental Application (Amneal Pharmaceuticals NY LLC)
The FDA approved a supplemental application for pirfenidone by Amneal Pharmaceuticals NY LLC, enabling the generic version to be marketed fo…
-
FDA approval · 2023-08-07FDA Approved: PIRFENIDONE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for pirfenidone from Sandoz Inc, enabling a generic version to enter the market.
-
FDA approval · 2023-08-07FDA Approved: PIRFENIDONE — Supplemental Application (Novadoz Pharmaceuticals LLC)
The FDA approved a supplemental application for pirfenidone filed by Novadoz Pharmaceuticals LLC.
-
FDA approval · 2023-08-07FDA Approved: PIRFENIDONE — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved a supplemental application for pirfenidone submitted by Alembic Pharmaceuticals Limited.
-
FDA approval · 2023-08-07FDA Approved: PIRFENIDONE — Supplemental Application (Sandoz Inc)
FDA approved Sandoz Inc's supplemental application for pirfenidone, a generic version of Esbriet, for the treatment of idiopathic pulmonary …
-
FDA approval · 2023-08-07FDA Approved: PIRFENIDONE — Supplemental Application (Amneal Pharmaceuticals NY LLC)
FDA approved a supplemental application for a generic pirfenidone from Amneal Pharmaceuticals NY LLC.
-
FDA approval · 2023-08-07FDA Approved: PIRFENIDONE — Supplemental Application (Camber Pharmaceuticals, Inc.)
The FDA approved a supplemental application for pirfenidone from Camber Pharmaceuticals (generic pirfenidone) for marketing, related to idio…
-
CLINICAL_TRIALS trial_result · 2023-06-28Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis [Phase 2]
Phase 2 trial evaluating CC-90001 for idiopathic pulmonary fibrosis was terminated; no results indicate efficacy or safety outcomes were pos…
-
CLINICAL_TRIALS trial_result · 2023-06-27Clinical Trial Update: The NIH Exercise Therapy for Advanced Lung Disease Trials: Response and Adaptation to Aerobic Exercise in Patients With Interstitial Lung Disease [NA]
Clinical trial update on aerobic exercise therapy for patients with interstitial lung disease, including idiopathic pulmonary fibrosis, comp…
-
FDA approval · 2023-05-31FDA Approved: PIRFENIDONE — Original Application (Apotex Corp.)
FDA approves Apotex Corp.'s original application for pirfenidone, a generic version of the IPF treatment.
-
CLINICAL_TRIALS trial_result · 2023-04-14Clinical Trial Update: Morphine Sulfate/Placebo for the Treatment of PulmonAry Fibrosis Cough [Phase 3]
Phase 3 trial evaluating morphine sulfate vs placebo for cough in idiopathic pulmonary fibrosis has completed.
-
CLINICAL_TRIALS trial_result · 2023-03-10Clinical Trial Update: Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis [Phase 2]
A Phase 2 study evaluating pharmacodynamics, pharmacokinetics, safety and tolerability of VAY736 in idiopathic pulmonary fibrosis was termin…
-
FDA approval · 2023-03-02FDA Approved: PIRFENIDONE — Supplemental Application (Accord Healthcare Inc.)
The FDA approved Accord Healthcare Inc.'s supplemental application to market a generic pirfenidone product for idiopathic pulmonary fibrosis…
-
FDA approval · 2023-02-24FDA Approved: ESBRIET — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for ESBRIET (pirfenidone) submitted by Genentech, Inc.
-
CLINICAL_TRIALS trial_result · 2022-12-22Clinical Trial Update: Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis. [EARLY_Phase 1]
Early Phase 1 trial evaluating LOXL2 and TGFbeta1 signaling inhibition for idiopathic pulmonary fibrosis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-11-01Clinical Trial Update: A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) [Phase 2]
A Phase 2 trial evaluating the impact of BI 1015550 taken for 12 weeks on lung function in idiopathic pulmonary fibrosis has completed with …